LOL... What is Ironic... Is you (and your ilk) are the exact people the BS from Citron influence.
Who Are the Top 10 Health Insurance Companies?
#1 – United Health Group
#2 – WellPoint, Inc.
#3 – Kaiser Foundation Group
#4 – Humana Group
#5 – Aetna Group
#6 – Health Care Service Corporation
#7 – Highmark Group
#8 – CIGNA Health Group
#9 – Coventry Corp. Group
#10 – Blue Shield of California
These 10 hold a 60% market share so it would be safe to assume that 60% of Acthar scripts (not sure how medicare or medicaid fit in) are represented by these 10 give or take... so my basic question is how can Citron and Cronies short stroke some obscure policy bulletin and time and again the UNH's of the world continue to cover Acthar as a second line treatment... I also believe we successfully debunked the Aetna policy bulletin that caused all of the hubub last year...
I am wondering if we can just put to bed the entire subject of policy bulletin's because even if an insurance company pushes back they (most of the time) will cover Acthar on appeal for justifiable patients... most individual insurance companies (100s) issue bulletins all the time and the shorts scream "SEE I TOLD YOU" insurance companies ain't gonna cover Acthar anymore... Forget the doctors forget the patients forget the efficacy forget MS, NS, ETC.... meanwhile with the exception of sna #$%$ in the first Q the quarterly reports have been nothing short of awsome.
Watch Citron come out with a quick update about New Fr i c ken Hampshire...
Also how big is Health Net? In rereading the bulletin... the only box check is for New Hampshire Medicaid... not sure if that is significant?
I read the bulletin... to my untrained eye... it simply reaffirms second line treatment when steroids are not tolerated... which is essentially the way it is with the other insurance carriers.
Any of the insurance coverage hawks care to comment?
NVS hired a company in 2002 (google it) to divest Synthetic Acthar... which at the time claimed 12,000,000 in global sales... 37 countries mind you... I guess NVS didn't have the time, inclination or vision of Don Baily...
1. QCOR (as Citron Asserts) buries Synthetic Acthar in the States. (which BTW isn't FDA approved)
2. QCOR actually does what the contractual aggreement says - and attempts FDA approval for certain indications and attempts to grow both Globally.... afterall they paid 200M (plus potential royalties)... Don Baily doesn't strike me as someone who wouldn't attempt this...
3. 50/50 - proceeds with some FDA testing in the States and expands markets in 37 countries, for not only synthetic acthar but also True Acthar
I fail to see which one of these scenarios QCOR loses... furthermore is there any precident where a company which legally owns a drug can be forced to introduce it in another country either by the FTC or FDA?
Remember this isn't GM buying Ford
1. Unsustanable Business Model - Oopps
2. High PE unsustainable - Partially True - but generally another Oopps due to point 1
3. Absence of R&D - Lupus and ALS - Oopps
4. Insurance Industry Pushback - Oopps
5. Imported from Canada - well thats true - But QCOR owns that now soooo - Oopss
6. Single digits in 18 Months - Oopss
I am sure there are more Oopss but I am tired - yawn
According to a Motly Fool Blogger he pins the cost at $1,000 not $10.00... which begs multiple questions:
1. How much of the synthetic acthar is acually sold in other coutries?
2. What is the cost?
3. If it has a resonable marging and market... can it not compete against 1st line therapies...
4. if so doesn't this create an actual market GLOBALLY that is much much bigger than the real Acthar?
As I ask these questions, ignoring the FDA requirements in the USA, the sum of the parts is potentially bigger, maybe much much much bigger than simply protecting Acthar in the States as Citron asserts.
Meanwhile, through all the Citron noise the actual paid analysts upticked price targets for QCOR in this Quarter...
Citron = Noise IMHO
which is more money than all of 2011... maybe in 2015 we can say the same about pulmonology... considering what appears to be a full scale ramping of efforts in this area... as witnessed by the multiple job postings.
PS why do the Citron Attacks simply seem point out the incredible growth of this company...
I thought of this question yesterday... Synacthen is a second tier drug that is "cheap" but really not being used... I tried googling some on this issue... Synacthen Sales? Anyone?
Hockey Stick Growth Curve... 1st 10 years was the blade... same with DDD SSYS... etc.... people are forgetting that they now have significant capital for the first time in their history... their goal should be to increase the installed base and make gain servicing parts print materials etc... proceeds from the IPO are directed towards creating new service centers globally... I would not rule out an acquisition either.... anyway, interesting stuff.
The Terror is going to surprise alot of people.... Not to mention they have like 50 shows in developement... while not all will air... many will and AMC has developed a loyal following, who watched Mad Men Breaking Bad and Walking Dead have been 3 of the best shows on TV.... they will at least give the show a chance before tuning out.
They Bashed DDD at 45... now 69 after hitting 84
They Bashed Z at 45... Now 72 after hitting 80+
They Bashed QCOR at 50 now 60 after hitting 74
I am sure their are more examples... I am not sure but there has to be something illegal about short and distort of guys like Citron....
Pretty sure the last time they said they bought back shares was 4th Q of 2012... which is surprising at best and #$%$ at worst.... Whilst I am enjoying the Dividend... The buyback needs to be implemented each quater... because as they say: "An Unused Weapon is a Useless Weapon"